In a preprint posted on BioRxiv this week, Decode researchers used nanopore sequencing to characterize structural variants in more than 1,800 Icelandic individuals.
The San Diego-based genomic analysis firm reported $3.3 million in revenue, driven by growth in North America sales, offset by a decline in international sales.
In Genome Biology this week: effect of structural variants in cancer, comparison of human and primate gut microbiomes, and more.
Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares.
Researchers uncovered examples of potentially beneficial copy number variants introgressed from Neanderthals and Denisovans under positive selection in Melanesians.
At ASHG, researchers showed why they're moving away from limited, linear human reference genome representations and towards a more inclusive future.
The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.
The San Diego-based genome mapping company attributed the drop in revenues to fewer international sales of its Saphyr platform.
The company reported $1.9 million in Q1 revenues amid a widened net loss of $7.9 million that was driven by increased operating expenses.
The project plans to sequence 20,000 genomes in 2019, 50,000 by the end of 2020, and a total of 100,000 by the end of 2021 using Oxford Nanopore's PromethIon platform.
Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.
MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.
Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.
In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.